Drug intelligence / Profile preview

ORK9

Development stage: Preclinical
Lead developer: Orikine Bio
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes

Overview

ORK9 is a preclinical-stage bi-specific cytokine developed by Orikine Bio using its proprietary Foldikine™ platform. Designed for oncology applications, ORK9 functions by reprogramming tumor-associated macrophages (TAMs) within the tumor microenvironment. By modulating these cells, the drug aims to shift the immune landscape from an immunosuppressive state to one that actively supports anti-tumor activity. As a Foldikine, ORK9 is a precision-engineered protein that combines multiple cytokine signaling activities into a single molecule to achieve therapeutic effects not possible with naturally occurring cytokines.

Other names: Foldikine

Beyond the preview

Go deeper on ORK9.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ORK9.

Explore the full profile